- recruitingTherapeutic exploratory (Phase II)
Synaptic density and tau pathology in Alzheimer’s disease (SYNAPSE)
This study looks at Alzheimer's disease using specialised brain scans. Researchers want to see how the loss of brain connections links to the build-up of a protein called tau. By measuring both in living patients, doctors hope to better understand how Alzheimer's develops and damages brain cells over time.
Netherlands - recruitingHuman Pharmacology (Phase I)- First administration to humans
A study investigating the safety, tolerability, pharmacokinetics (absorption, distribution, metabolism and elimination) and effect of single and multiple doses of MTX46943, a new compound that may potentially be used in the treatment of Alzheimer’s disease and other neurological disorders
This early-stage study is testing a new medicine called MTX46943 in humans for the first time. Researchers want to check if the treatment is safe, see how the body handles it, and find out whether it could help treat Alzheimer’s disease and other brain conditions in the future.
Netherlands - recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
This study is looking at a new potential medicine, DNL921, for Alzheimer's disease. Researchers want to see if it's safe, how the body handles it, and how it affects the body. They're testing it in healthy people and those with early Alzheimer's.
United Kingdom - recruitingTherapeutic exploratory (Phase II)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate Alzheimer's Disease
This study is testing a new medicine, GV1001, for people with mild to moderate Alzheimer's disease. We want to see if it's safe and if it can help improve memory and thinking over 52 weeks. Half the participants will receive the medicine, and half will receive a dummy injection.
Italy · Portugal · Poland - recruitingHuman Pharmacology (Phase I)- First administration to humans
A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)
This study is looking into a new medicine called IBC-Ab002 for people with early Alzheimer's disease. It's the very first time this medicine is being given to humans, to see if it's safe and how it works in the body.
Netherlands - recruitingHuman Pharmacology (Phase I)- First administration to humans
A phase 1, controlled, open-label, single dose, dose-escalation, clinical proof-of-concept study of MRI enhanced with ADx-001 (DSPE-DOTA-Gd Liposomal Injection) in patients with brain amyloid deposits as demonstrated by amyloid PET
This study is looking at a new injection called ADx-001 that might help doctors see signs of Alzheimer's disease in the brain more clearly on MRI scans. It's an early-stage study to see if it's safe and how it works in people.
Germany - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Randomised, crossover bioequivalence clinical trial of memantine 20 mg capsules versus memantine 20 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions.
This study is comparing two ways to take the Alzheimer's medicine memantine: capsules versus coated tablets. Healthy adults will take a single dose to see if both forms work the same way in the body.
Spain - recruitingTherapeutic exploratory (Phase II)
A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.
This study is looking at the long-term safety and how well a new medicine, GSK4527226 (also known as AL101), works for people with early Alzheimer's disease. Researchers want to see if it helps with memory and daily activities over a longer period.
Sweden · Norway · Italy - active not recruitingPHASE3
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
This study, called TRAILRUNNER-ALZ 3, is looking at a new medicine called Remternetug for people in the early stages of Alzheimer's disease. Researchers want to see if it can slow down memory, thinking, or daily living problems compared to a dummy drug (placebo).
United States · Australia · Canada - recruitingPHASE2
Open-label Extension Study in Participants With Early Alzheimer's Disease
This study is looking into a new medication called GSK4527226 for people with early Alzheimer's disease. It's an extension of an earlier study, meaning everyone in this new phase will receive the treatment. We're checking how safe and effective it is over the long term.
United States · Argentina · Australia - recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Randomised, crossover bioequivalence clinical trial of donepezil 5 mg capsules vs donepezil 5 mg film-coated tablets, after a single oral dose administration to healthy volunteers under fasting conditions
This study is comparing two ways of taking the same Alzheimer's medicine, donepezil. It looks at whether a 5mg capsule works in the body similarly to a 5mg tablet when taken by healthy volunteers on an empty stomach.
Spain - recruitingTherapeutic exploratory (Phase II)
A Patient- and Investigator-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Study Participants With Prodromal to Mild Alzheimer’s Disease (AD), Followed by an Open-Label Extension Period
This study is testing a new medicine called Bepranemab for people with early Alzheimer's disease. Researchers want to see if it's safe and helps with memory and thinking, compared to a dummy drug. It's a key step in understanding if this treatment could work.
Italy · Spain · Germany - recruitingHuman Pharmacology (Phase I)- Other
A PHASE 1, OPEN-LABEL, RANDOMIZED, THREE-PERIOD, THREE-TREATMENT, BALANCED, SIX-SEQUENCE CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF DIFFERENT HYDROMETHYLTHIONINE MESYLATE (HMTM) TABLET FORMULATIONS AND STRENGTHS IN HEALTHY ADULT SUBJECTS.
This study is testing different versions of a new medicine called hydromethylthionine mesylate (HMTM) in healthy adults. We want to see how well the body absorbs each version. This research might help us find better ways to treat diseases like Alzheimer's.
Netherlands - recruitingHuman Pharmacology (Phase I)- Other
Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102
This study is an open-label extension, meaning everyone gets the study drug. It's for people with Alzheimer's disease who have already taken part in previous PRX012 studies (PRX012-101 or PRX012-102) to see how the treatment works long-term.
Spain · Poland - recruitingNot Specified
Trialling a blood test for Alzheimer’s disease in UK memory services
This study is testing a new blood test for earlier and more accurate Alzheimer's disease diagnosis in UK memory clinics. It aims to see if this test can help doctors make a quicker diagnosis for people aged 50 and over who have memory problems.
United Kingdom · England · Scotland - recruitingTherapeutic exploratory (Phase II)
A Multicenter, Long-term Extension Study to Evaluate the Safety, Tolerability, and Efficacy of AL002 in Participants with Alzheimer's Disease
This study is looking at a new treatment called AL002 for Alzheimer's disease. Researchers want to see if it's safe, how well people can cope with it, and if it helps reduce symptoms over a long time. It’s for adults diagnosed with Alzheimer's.
Germany · Netherlands · Spain - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared with Placebo in Patients with Early Alzheimer’s Disease
This study is testing a new medicine called GSK4527226 (also known as AL101) for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and if it can help improve memory and thinking compared to a dummy treatment.
Germany · Netherlands · Finland - recruitingPHASE3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
This study is looking into a new treatment called KarXT + KarX-EC for agitation (feeling restless or upset) in people with Alzheimer's disease. It wants to see if the treatment is safe and if it helps reduce agitation.
United States · Argentina · Chile - recruitingPHASE2
Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia
This study is looking at a new way to help people with Alzheimer's disease who feel unmotivated or apathetic. It combines a brain stimulation method with a commonly used medicine to see if it can improve these feelings.
Canada - recruitingPHASE3
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
This study is looking into a new medication called Trontinemab for people who are at risk of developing Alzheimer's disease but don't yet have symptoms. We want to see if it's safe and if it can help slow down or stop the disease from progressing.
United States · Argentina · Australia - recruiting
The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)
This study, called "The Monument Test," looks at how people with Alzheimer's disease and healthy older adults identify and name famous monuments. It helps researchers understand memory changes in Alzheimer's. Participants will complete a naming and identification task.
France - active not recruitingPHASE2
A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)
This study is for people aged 60-85 at risk of Alzheimer's or with very early memory problems. It tests a new potential medicine, RO7269162, to see if it's safe and affects the disease. Participants will receive the new medicine or a dummy treatment, with regular check-ups.
Chile · Denmark · France - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
This study is looking into a new treatment called KarXT + KarX-EC for people with mild to moderate Alzheimer's disease. Researchers want to see if it can help improve memory and thinking, and if it's safe to use.
United States · Argentina · Australia - enrolling by invitationPHASE2
TSPO Modulation in AD
This study looks at a new drug, XBD173, for Alzheimer’s disease. It wants to see if the drug can improve how blood flows to the brain, which is important for brain health and memory. The drug is taken for 28 days.
United Kingdom - recruitingNA
Social & Affective Cognition in Alzheimer's Disease & Associated Disorders
This study looks at how well people with Alzheimer's and similar brain conditions understand social situations and emotions. Researchers want to see if this understanding is linked to changes in their behaviour and which parts of the brain are involved.
France - recruitingPHASE1
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
This study is testing a new medicine called ALN-5288 for people with Alzheimer's disease. Researchers want to see if it's safe and how it affects the body and the disease. Some people will get the study drug, and others will get a dummy medicine.
Canada · Netherlands · Spain - recruitingPHASE1, PHASE2
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
This study is looking at a new treatment called ACI-24.060. It aims to see if it's safe and how it works in people with early Alzheimer's disease and adults with Down Syndrome who have signs of Alzheimer's. The goal is to understand if it can help prevent or slow down these conditions.
United States · Spain · United Kingdom - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
This study is looking at a new medicine called KarXT + KarX-EC to see if it can help improve memory and thinking skills in people with Alzheimer's disease. It also checks if the medicine is safe to use. Some people will get the active medicine, others a dummy pill.
United States · Argentina · Australia - recruiting
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
This study looks for early signs of Alzheimer's disease by examining blood, brain scans, and digital information. It aims to find new ways to spot the disease before it gets worse, especially in people with memory problems or those who are still healthy.
United States · Canada · United Kingdom - active not recruitingPHASE3
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This study is looking at different ways of giving a medicine called donanemab for early Alzheimer's disease. Researchers want to see how different doses affect side effects and which patients might be more likely to experience them. It's for adults aged 60-85.
United States · United Kingdom - active not recruitingPHASE2
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
This study is testing a new medicine, GSK4527226, for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow down symptoms compared to a dummy medicine.
United States · Argentina · Australia - not yet recruitingNA
An Investigation Into the Feasibility of Beetroot Juice Supplementation in People Living With Alzheimer's Disease.
This study looks at whether people with Alzheimer's can easily drink beetroot juice regularly. Researchers want to see if drinking beetroot juice twice a day for one week can improve health for those with mild or moderate Alzheimer’s disease.
United Kingdom - authorisedHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease
This study is looking at a new medicine called ALN-5288 for people with Alzheimer's disease. Researchers want to see if it's safe and how the body handles it. This is a very early stage study, meaning it's the first time this medicine is being given to people.
Spain · Netherlands - active not recruitingPHASE1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
This study is testing a new medication called RO7812653 for early Alzheimer's disease. Researchers want to see if it's safe, how the body handles it, and if it has any effects. They are comparing it to a dummy treatment (placebo) in people aged 50-75.
Canada · Netherlands · Spain - recruiting
Dominantly Inherited Alzheimer Network (DIAN)
This study looks for early signs of Alzheimer's disease in people who have a family history of the condition. It aims to find ways to predict who will develop the disease, even before symptoms appear, by studying changes in their body and brain.
United States · Argentina · Australia - active not recruitingPHASE3
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
This study looks at a new drug, lecanemab, to see if it can fully remove amyloid plaques in people with a rare, inherited form of Alzheimer's. It also checks if removing these plaques can slow down how quickly the disease progresses.
United States · Australia · United Kingdom - recruitingPHASE2
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
This study is looking into a new treatment called VHB937 for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps with memory and daily activities. It involves taking the treatment or a dummy pill and having regular check-ups.
United States · Australia · Canada - recruitingNA
The Role of METhanogens in the PROgression Of Parkinson's Disease and Related Neurological Conditions
This study looks at how gut health, especially methane gas levels, might be linked to Parkinson's disease and memory problems. It also tests if a probiotic can help reduce methane. We want to understand if gut issues affect how these conditions develop and progress.
United Kingdom